Stock Analysis

CK Life Sciences Int'l. (Holdings) (HKG:775) sheds HK$529m, company earnings and investor returns have been trending downwards for past three years

Published
SEHK:775

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But long term CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) shareholders have had a particularly rough ride in the last three year. Unfortunately, they have held through a 60% decline in the share price in that time. And over the last year the share price fell 54%, so we doubt many shareholders are delighted. Furthermore, it's down 19% in about a quarter. That's not much fun for holders.

After losing 14% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

View our latest analysis for CK Life Sciences Int'l. (Holdings)

While CK Life Sciences Int'l. (Holdings) made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues.

In the last three years, CK Life Sciences Int'l. (Holdings) saw its revenue grow by 1.5% per year, compound. Given it's losing money in pursuit of growth, we are not really impressed with that. It's likely this weak growth has contributed to an annualised return of 17% for the last three years. When a stock falls hard like this, some investors like to add the company to a watchlist (in case the business recovers, longer term). Keep in mind it isn't unusual for good businesses to have a tough time or a couple of uninspiring years.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

SEHK:775 Earnings and Revenue Growth June 3rd 2024

If you are thinking of buying or selling CK Life Sciences Int'l. (Holdings) stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

While the broader market gained around 5.3% in the last year, CK Life Sciences Int'l. (Holdings) shareholders lost 54%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 1.6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 4 warning signs for CK Life Sciences Int'l. (Holdings) (2 are potentially serious!) that you should be aware of before investing here.

We will like CK Life Sciences Int'l. (Holdings) better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.